Results 61 to 70 of about 12,886 (187)

B cell subsets reconstitution and immunoglobulin levels in children and adolescents with B non-Hodgkin lymphoma after treatment with single anti CD20 agent dose included in chemotherapeutic protocols: single center experience and review of the literature

Biomedical Papers
Background. RTX, an anti-CD20 monoclonal antibody, added to chemotherapy has proven to be effective in children and adolescents with high-grade, high-risk and matured non-Hodgkin lymphoma. RTX leads to prompt CD19+ B lymphocyte depletion.
Eva Hlavackova, Zdenka Krenova, Arpad Kerekes, Peter Slanina, Marcela Vlkova   +4 more
doaj   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 9, Page 2177-2189, September 2026.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source

Case Report: Hypomorphic Ligase 4 deficiency – a paradigm of immunodysregulation

Frontiers in Immunology
DNA Ligase 4 is critical to nonhomologous end joining, necessary for V(D)J recombination in T and B cell development. Ligase 4 deficiency is a rare autosomal recessive disorder caused by hypomorphic mutations in the DNA Ligase 4 gene, that can lead to a ...
Catarina Andrade, Ana Isabel Cordeiro, Marta Valente Pinto, Marta Valente Pinto, Conceição Neves, Catarina Martins, Jean-Pierre Villartay, João Farela Neves, João Farela Neves   +8 more
doaj   +1 more source

Biosimilar Rituximab in ANCA‐Associated Vasculitis Compared to the Originator: A Multicenter Cohort Study

ACR Open Rheumatology, Volume 8, Issue 8, August 2026.
Objective To evaluate the six‐month effectiveness and safety of rituximab biosimilars compared to the originator in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and outcomes following originator to biosimilar switching. Methods We recruited adults with GPA or MPA treated with the rituximab originator or a biosimilar for ...
Arielle Mendel, Lillian Barra, Hassan Behlouli, Sasha Bernatsky, Alison H. Clifford, Jan Willem Cohen Tervaert, Natasha Dehghan, Aurore Fifi‐Mah, Jean‐Paul Makhzoum, Rosalie‐Sélène Meunier, Nataliya Milman, Medha Soowamber, Elaine Yacyshyn, Nader Khalidi, Christian Pagnoux   +14 more
wiley   +1 more source

A Case Report of a Patient With Recalcitrant Pemphigus Vulgaris Treated With Rituximab

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Pemphigus vulgaris may demonstrate differential treatment responses across disease sites. In this case, cutaneous lesions responded to high‐dose corticosteroids, whereas refractory oral disease required rituximab to achieve remission, highlighting the need for individualized, multimodal therapy to achieve sustained disease control.
Mahlatse Cordelia Kgokolo, Lesedi Makgwethele Nevondo, Michaela Beetge, Razia A. G. Khammissa   +3 more
wiley   +1 more source

Hypogammaglobulinemia with Facial Edema

PLoS Medicine, 2006
Knight and colleagues discuss the diagnosis and management of a 35-year-old man with a past history of recurrent cellulitis and otitis media and a two-year history of facial swelling.
Adina Kay Knight, Lloyd Mayer, Andrew G Franks, Charlotte Cunningham-Rundles   +3 more
openaire   +4 more sources

Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2‐Year Follow‐Up From MajesTEC‐1 China Cohort

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction With an additional year of follow‐up compared with the previous report, this study presents the 27.2‐month efficacy and safety outcomes of the MajesTEC‐1 China cohort. Methods A total of 26 participants with triple‑class exposed relapsed/refractory multiple myeloma (TCE‐RRMM) received subcutaneous teclistamab 1.5 mg/kg weekly ...
Zhen Cai, Zhongjun Xia, Aili He, Yujun Dong, Yafei Wang, Aijun Liao, Yang Song, Hongye Chen, Athena Zuppa, Katherine Chastain, Latisha Watkins, Xinchao Luo, Lin Huang, Hongmei Xu, Longen Zhou, Wannan Chen, Angeline Zhu, Xiaohong Wang, Weijun Fu, Ting Niu, Juan Du   +20 more
wiley   +1 more source

Targeting CD162 for Life‐Threatening Cutaneous Chronic Graft‐Versus‐Host Disease: A Case Report

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Steroid‐refractory chronic cutaneous graft‐versus‐host disease (GVHD) causes substantial morbidity, prolonged hospitalization, and non‐relapse mortality after allogeneic hematopoietic cell transplantation. We report a young adult with multisystem chronic GVHD and recurrent life‐threatening inflammatory skin flares refractory to multiple ...
Alicia Lieberman, Ross McCauley, Maureen Ross, Philip McCarthy, Iming Cho, Simona Reed, Shih‐Yao Lin, Judy Chou, Shernan G. Holtan   +8 more
wiley   +1 more source

Diagnostic Immunization with Bacteriophage ΦX 174 in Patients with Common Variable Immunodeficiency/Hypogammaglobulinemia

Frontiers in Immunology, 2014
Purpose: Use of the T cell-dependent neoantigen bacteriophage ΦX 174 has been described since the 1960s as a method to assess specific antibody response in patients with primary immunodeficiencies.
Lauren L Smith, Rebecca eBuckley, Patricia eLugar   +2 more
doaj   +1 more source

A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent‐Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6584-6594, August 2026.
ABSTRACT Introduction Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin‐producing pancreatic β‐cells. Preserving remaining β‐cells at the time of diagnosis may improve long‐term outcomes. Frexalimab is a humanised monoclonal antibody specific for CD40L undergoing evaluation for treatment of ...
Andriy Cherkas, Baerbel Rotthaeuser, Niels Porksen, Pascale Labard, My‐Liên Nguyên‐Pascal, Mathieu Coudert, Baptiste Berthou, Marie Baccara‐Dinet, Gabor Boka, Mark Peakman, Felix Reschke, Michael J. Haller   +11 more
wiley   +1 more source